MA71118B1 - Anticorps anti-c5 et leurs utilisations - Google Patents

Anticorps anti-c5 et leurs utilisations

Info

Publication number
MA71118B1
MA71118B1 MA71118A MA71118A MA71118B1 MA 71118 B1 MA71118 B1 MA 71118B1 MA 71118 A MA71118 A MA 71118A MA 71118 A MA71118 A MA 71118A MA 71118 B1 MA71118 B1 MA 71118B1
Authority
MA
Morocco
Prior art keywords
antibodies
bind
protein
neutralizing
disorder
Prior art date
Application number
MA71118A
Other languages
English (en)
Inventor
Ying Hu
Adrianna Latuszek
William Olson
Carmelo Romano
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of MA71118B1 publication Critical patent/MA71118B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)

Abstract

La présente invention concerne des anticorps monoclonaux qui se lient à la protéine du facteur 5 du complément (C5), ainsi que leurs méthodes d'utilisation. Dans divers modes de réalisation de l'invention, les anticorps sont des anticorps entièrement humains qui se lient à la protéine C5. Dans certains modes de réalisation, les anticorps de l'invention sont utiles pour inhiber ou neutraliser l'activité du C5, offrant ainsi un moyen de traiter ou de prévenir une maladie ou un trouble lié au C5 chez l'homme. Dans certains modes de réalisation, l'invention prévoit un anticorps anti-C5 doté de propriétés pharmacocinétiques et pharmacodynamiques améliorées, par exemple une demi-vie supérieure à 10 jours.
MA71118A 2016-06-14 2017-06-13 Anticorps anti-c5 et leurs utilisations MA71118B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662349705P 2016-06-14 2016-06-14
US201662405561P 2016-10-07 2016-10-07
US201662422107P 2016-11-15 2016-11-15
EP24156366.7A EP4374922B1 (fr) 2016-06-14 2017-06-13 Anticorps anti-c5 et leurs utilisations

Publications (1)

Publication Number Publication Date
MA71118B1 true MA71118B1 (fr) 2026-04-30

Family

ID=59091673

Family Applications (2)

Application Number Title Priority Date Filing Date
MA45235A MA45235B1 (fr) 2016-06-14 2017-06-13 Anticorps anti-c5 et leurs utilisations
MA71118A MA71118B1 (fr) 2016-06-14 2017-06-13 Anticorps anti-c5 et leurs utilisations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA45235A MA45235B1 (fr) 2016-06-14 2017-06-13 Anticorps anti-c5 et leurs utilisations

Country Status (29)

Country Link
US (4) US10633434B2 (fr)
EP (3) EP4706763A3 (fr)
JP (4) JP7102353B2 (fr)
KR (3) KR102667023B1 (fr)
CN (3) CN109563159B (fr)
AU (2) AU2017283470B2 (fr)
CA (1) CA3027487A1 (fr)
CL (1) CL2018003563A1 (fr)
CO (1) CO2018014413A2 (fr)
DK (1) DK3468990T3 (fr)
ES (1) ES2984352T3 (fr)
FI (2) FI3468990T3 (fr)
HR (1) HRP20240815T1 (fr)
HU (1) HUE067224T2 (fr)
IL (3) IL309975B2 (fr)
LT (1) LT3468990T (fr)
MA (2) MA45235B1 (fr)
MD (1) MD3468990T2 (fr)
MX (3) MX2018015149A (fr)
MY (3) MY196220A (fr)
PH (2) PH12018502560B1 (fr)
PL (1) PL3468990T3 (fr)
PT (1) PT3468990T (fr)
RS (1) RS65633B1 (fr)
SG (2) SG10202012243VA (fr)
SI (1) SI3468990T1 (fr)
SM (2) SMT202400269T1 (fr)
UA (1) UA124734C2 (fr)
WO (1) WO2017218515A1 (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2275443B1 (fr) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l antigène capable de se lier à deux molécules d antigène ou plus de manière répétée
PY09026846A (es) * 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
ME03043B (fr) 2013-03-14 2018-10-20 Alnylam Pharmaceuticals Inc Compositions d'arni du constituant c5 du complément et leurs procédés d'utilisation
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SG10201710322VA (en) 2014-12-19 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
WO2016125495A1 (fr) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Anticorps comprenant un domaine se liant à l'antigène dépendant de la concentration d'ions, variants de la région fc, anticorps se liant à l'il-8, et leurs utilisations
AU2017269839A1 (en) 2016-05-27 2018-11-22 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
WO2017218515A1 (fr) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anticorps anti-c5 et leurs utilisations
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
BR112019018429A2 (pt) * 2017-03-06 2020-04-14 Univ Pennsylvania anticorpo, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indíviduo e para reduzir a atividade de um sistema complemento de um indivíduo, e, célula
BR112020001703B1 (pt) 2017-07-27 2024-01-02 Alexion Pharmaceuticals, Inc Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma
EP3694545A4 (fr) 2017-10-11 2021-12-01 Board Of Regents, The University Of Texas System Anticorps pd-l1 humains et leurs procédés d'utilisation
EP3700928A1 (fr) 2017-10-26 2020-09-02 Alexion Pharmaceuticals, Inc. Dosage et administration d'anticorps anti-c5 pour le traitement de l'hémoglobinurie paroxystique nocturne (pnh) et du syndrome hémolytique et urémique atypique (ahus)
MX2020006113A (es) 2017-12-13 2020-08-24 Regeneron Pharma Combinaciones de anticuerpos anti-c5 y usos de las mismas.
US20190247560A1 (en) * 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
WO2019182867A1 (fr) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Anticorps à double spécificité pour pd-l1 et pd-l2 humains et leurs procédés d'utilisation
CA3092695A1 (fr) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Anticorps anti-pd-l2 humains et leurs procedes d'utilisation
US12187799B2 (en) 2018-03-23 2025-01-07 Board Of Regents, The University Of Texas System Dual specificity antibodies to PD-L1 and PD-L2 and methods of use therefor
US12410234B2 (en) 2018-04-26 2025-09-09 The Trustees Of The University Of Pennsylvania Compositions and methods for retrieving tumor-related antibodies and antigens
US12404320B2 (en) * 2018-05-31 2025-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
JP7577542B2 (ja) 2018-06-04 2024-11-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
EP3814373A1 (fr) 2018-06-28 2021-05-05 Alexion Pharmaceuticals, Inc. Procédés de production d'anticorps anti-c5
US12098190B2 (en) * 2018-09-06 2024-09-24 The Trustees Of The University Of Pennsylvania And Humanized anti-C5 antibodies and uses thereof
US20220056115A1 (en) * 2018-09-17 2022-02-24 Kyoto University Administration of an anti-c5 agent for treatment of hepatic injury or failure
JP2022501378A (ja) 2018-09-21 2022-01-06 アレクシオン ファーマシューティカルズ インコーポレイテッドAlexion Pharmaceuticals, Inc. 視神経脊髄炎の処置のためのエクリズマブ
MX2021004994A (es) 2018-10-30 2021-06-15 Alexion Pharma Inc Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh).
WO2020092546A1 (fr) 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Co-administration d'une hyaluronidase et d'un anticorps anti-c5 pour le traitement d'états associés au complément
CN113614105A (zh) 2019-01-25 2021-11-05 亚力兄制药公司 用于治疗非典型溶血性尿毒综合征(ahus)的抗c5抗体的剂量和施用
CN113614106A (zh) 2019-02-14 2021-11-05 亚力兄制药公司 抗c5抗体用于治疗全身型重症肌无力的剂量和施用
WO2020242849A1 (fr) 2019-05-24 2020-12-03 Alexion Pharmaceuticals, Inc. Procédés de traitement du vitiligo à l'aide d'un anticorps anti-c5
WO2021026160A1 (fr) 2019-08-05 2021-02-11 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la myasthénie grave généralisée réfractaire avec de l'eculizumab
AU2020334880A1 (en) * 2019-08-16 2022-03-24 Regeneron Pharmaceuticals, Inc. High concentration anti-C5 formulations
US20220356234A1 (en) 2019-10-02 2022-11-10 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
AU2020369581A1 (en) 2019-10-25 2022-04-21 Regeneron Pharmaceuticals, Inc. Dosing regimens for treating or preventing C5-associated diseases
WO2021102267A1 (fr) * 2019-11-20 2021-05-27 Cornell University Génération de cellules endothéliales spécifiques du glomérule rénal et procédés d'utilisation
WO2021118999A1 (fr) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Anticorps anti-c5 pour le traitement de trouble du spectre de la neuromyélite optique
JP7734673B2 (ja) 2019-12-23 2025-09-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体を使用して妊娠関連非典型溶血性尿毒症症候群を治療する方法
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN111234016B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的全人源单克隆抗体及应用
CN113563467A (zh) * 2020-04-28 2021-10-29 上海普铭生物科技有限公司 针对人补体蛋白c5的抗体及其应用
EP4142738A1 (fr) 2020-04-30 2023-03-08 Alnylam Pharmaceuticals, Inc. Compositions d'arni du facteur b du complément (cfb) et leurs procédés d'utilisation
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
WO2021231470A1 (fr) 2020-05-12 2021-11-18 Alexion Pharmaceuticals, Inc. Utilisation d'inhibiteurs du facteur d du complément seuls ou en combinaison avec des anticorps anti-c5 pour le traitement de l'hémoglobinurie paroxystique nocturne
EP4150338A1 (fr) 2020-05-15 2023-03-22 Alexion Pharmaceuticals, Inc. Méthode d'utilisation de vésicules extracellulaires pour détecter une activation du complément, et leurs utilisations pour l'évaluation et/ou la surveillance du traitement d'une maladie à médiation par le complément
CN113754763B (zh) * 2020-06-05 2024-03-08 天辰生物医药(苏州)有限公司 分离的抗原结合蛋白及其用途
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下（sc）施用抗c5抗体治疗补体相关病症
US20230235035A1 (en) * 2020-07-09 2023-07-27 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treating paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
WO2022036151A1 (fr) 2020-08-13 2022-02-17 Alexion Pharmaceuticals, Inc. Dosage et administration d'anticorps anti-c5 pour le traitement de la microangiopathie thrombotique associée à une greffe de cellules souches hématopoïétiques (hsct-tma)
EP4213940A1 (fr) 2020-09-21 2023-07-26 Alexion Pharmaceuticals, Inc. Dosage et administration d'anticorps anti-c5 pour le traitement de la néphrite glomérulaire à médiation par c5 (gn), y compris la néphrite lupique (ln) et/ou la néphropathie à l'iga (igan)
WO2022087339A1 (fr) 2020-10-23 2022-04-28 Alexion Pharmaceuticals, Inc. Méthodes de traitement de patients atteints de troubles du complément à l'aide d'anticorps anti-c5
EP4378479A3 (fr) 2021-01-22 2024-09-25 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la microangiopathie thrombotique à médiation par le complément à l'aide d'un anticorps anti-c5
EP4348263A1 (fr) 2021-05-28 2024-04-10 Alexion Pharmaceuticals, Inc. Procédés de détection de biomarqueurs cm-tma
WO2022265915A1 (fr) 2021-06-14 2022-12-22 Alexion Pharmaceuticals, Inc. Dosage et administration d'anticorps anti-c5 pour le traitement de la dermatomyosite (dm)
US20250154232A1 (en) 2021-07-14 2025-05-15 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis
WO2023023220A1 (fr) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la drépanocytose ou de la bêta-thalassémie à l'aide d'un inhibiteur de la voie alterne du complément
WO2023050233A1 (fr) * 2021-09-29 2023-04-06 The Trustees Of The University Of Pennsylvania Anticorps anti-c5a humanisés et leurs utilisations
JP2024540086A (ja) 2021-10-28 2024-10-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃ５をノックアウトするためのｃｒｉｓｐｒ／ｃａｓ関連方法及び組成物
CA3234636A1 (fr) 2021-10-29 2023-05-04 Alnylam Pharmaceuticals, Inc. Compositions d'arni du facteur b du complement (cfb) et leurs procedes d'utilisation
KR20250057830A (ko) * 2022-08-30 2025-04-29 롱바이오 파마 (수조우) 컴퍼니 리미티드 항-인간 보체 c5 항체 및 이의 융합 단백질
TW202426048A (zh) 2022-09-06 2024-07-01 美商阿雷希昂製藥公司 用於治療造血幹細胞移植相關血栓性（ｈｓｃｔ－ｔｍａ）的抗ｃ５抗體的補充劑量和投與
CN120035450A (zh) 2022-09-06 2025-05-23 阿雷克森制药公司 造血干细胞移植物相关血栓性微血管病（hsct-tma）患者的诊断和预后生物标志物谱
TW202423479A (zh) 2022-09-28 2024-06-16 美商阿雷希昂製藥公司 用於預防或最小化患有慢性腎病的患者中的心臟手術相關急性腎損傷（csa-aki）和/或隨後的主要不良腎事件（make）的抗c5抗體之劑量及投與
WO2024238421A1 (fr) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Utilisation de biomarqueurs pour l'identification et le traitement de troubles médiées par le complément
WO2024238422A1 (fr) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Utilisation d'un panel de lectines pour la détection de biomarqueurs du complément dans des vésicules extracellulaires d'urine
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
IL327001A (en) 2024-02-02 2026-05-01 Alexion Pharmaceuticals Inc Dosage and administration of anti-C5 antibodies for the treatment of IGA nephropathy (IGAN)
WO2025221479A1 (fr) 2024-04-16 2025-10-23 Alexion Pharmaceuticals, Inc. Biomarqueurs pour surveiller un traitement efficace d'un trouble du spectre de la neuromyélite optique (nmosd) avec des inhibiteurs du composant c5 du complément
US20260097063A1 (en) 2024-10-01 2026-04-09 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody/c5 irna dosing regimens for treating c5-associated diseases
CN119409815B (zh) * 2025-01-07 2025-04-08 天辰生物医药(苏州)有限公司 抗人补体c5 vhh抗体及其应用

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
DE69233010T2 (de) 1991-07-15 2004-02-19 Oklahoma Medical Research Foundation, Oklahoma Universale spenderzellen
WO1994000560A1 (fr) 1992-06-29 1994-01-06 Alexion Pharmaceuticals, Inc. Matrice de cellules endotheliales microvasculaires et donneuses universelles
EP0751787B1 (fr) 1994-03-23 2005-01-12 Alexion Pharmaceuticals, Inc. Procede permettant de reduire les dysfonctionnements des systemes immunitaire et hemostatique pendant la circulation extra-corporelle
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5562904A (en) 1994-07-21 1996-10-08 Alexion Pharmaceuticals, Inc. Retroviral transduction of cells using soluble complement inhibitors
ES2252746T3 (es) 1994-09-23 2006-05-16 Alexion Pharmaceuticals, Inc. Procedimientos para el tratamiento de la enfermedad inflamatoria articular.
US6673346B1 (en) 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
EP2113516B1 (fr) 2000-10-10 2014-05-21 Genentech, Inc. Anticorps contre C5 inhibant l'activation de type II des cellules endothéliales
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2457461C (fr) 2001-08-17 2013-12-24 Tanox, Inc. Inhibiteur de la voie du complement se fixant a c5 et a c5a sans empecher la formation de c5b
EP3372243A1 (fr) * 2001-08-17 2018-09-12 Genentech, Inc. Inhibiteurs de chemin d'accès complémentaires liant c5 et c5a sans empêcher la formation de c5b
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
ES2614274T3 (es) 2002-09-06 2017-05-30 Alexion Pharmaceuticals, Inc. Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
KR20110017020A (ko) 2002-10-17 2011-02-18 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
JP4597976B2 (ja) 2003-04-17 2010-12-15 アルナイラム ファーマシューティカルズ インコーポレイテッド 修飾ｉＲＮＡ剤
EP1629098B1 (fr) 2003-06-02 2009-04-01 Varleigh Limited Inhibiteurs du complement
KR101076516B1 (ko) 2003-09-08 2011-10-24 파나소닉 주식회사 플라즈마 처리방법 및 장치
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
WO2005103081A2 (fr) 2004-04-20 2005-11-03 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
NZ551308A (en) 2004-05-14 2009-06-26 Alexion Pharma Inc Prolongation of survival of an allograft by inhibiting complement activity
US7763708B2 (en) 2004-08-12 2010-07-27 Institute For Protein Science Co., Ltd. Methods and compositions for modulating C5-a-mediated inflammatory responses
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
PT2500030E (pt) 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
AU2013200223B2 (en) 2005-11-04 2015-08-20 Genentech, Inc. Use of Complement Pathway Inhibitors to Treat Ocular Diseases
AU2007224250B2 (en) 2006-03-02 2012-05-03 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
ES2965283T3 (es) 2006-03-15 2024-05-28 Alexion Pharma Inc Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
KR101503540B1 (ko) 2006-09-05 2015-03-17 알렉시온 파마슈티칼스, 인코포레이티드 항체 매개된 신경병증의 치료를 위한 방법과 조성물
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
PL2061501T3 (pl) 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
SI3028716T1 (sl) 2006-10-10 2021-01-29 Regenesance B.V. Komplementarna inhibicija za izboljšano regeneracijo živcev
AU2008214359B2 (en) 2007-02-05 2014-01-16 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
AR069130A1 (es) 2007-11-02 2009-12-30 Novartis Ag Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento
EP2275443B1 (fr) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l antigène capable de se lier à deux molécules d antigène ou plus de manière répétée
US8250207B2 (en) 2009-01-28 2012-08-21 Headwater Partners I, Llc Network based ambient services
AU2014201433B2 (en) 2008-08-05 2016-05-26 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
US8445190B2 (en) 2008-09-30 2013-05-21 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
US9891219B2 (en) 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
US9447176B2 (en) 2008-11-10 2016-09-20 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
KR20120105405A (ko) 2009-06-23 2012-09-25 알렉시온 파마슈티칼스, 인코포레이티드 보체 단백질에 결합하는 이중특이적 항체
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
EP2454623A1 (fr) 2009-07-17 2012-05-23 Corning Cable Systems LLC Rubans de fibres optiques, et matériau de matrice pour rubans à faible teneur en oligomères
EP2327725A1 (fr) 2009-11-26 2011-06-01 InflaRx GmbH Groupes caractéristiques à liaison anti-C5a avec une activité à blocage élevé
EP2521562B1 (fr) 2010-01-08 2019-09-18 Volution Immuno Pharmaceuticals SA Ev576 pour utilisation dans traitement d'infections virales des voies respiratoires
HRP20151188T4 (hr) 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
CA2791962A1 (fr) 2010-03-01 2011-09-09 Alexion Pharmaceuticals, Inc. Methodes et compositions pour le traitement de la maladie de degos
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
JP6022441B2 (ja) 2010-04-30 2016-11-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗Ｃ５ａ抗体およびその抗体の使用のための方法
AU2015201676B2 (en) 2010-04-30 2016-10-13 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
MX2012014975A (es) * 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
WO2012145746A1 (fr) 2011-04-21 2012-10-26 The Regents Of The University Of Colorado, A Body Corporate Compositions et méthodes de traitement de maladie de devic
ES2728278T3 (es) 2011-12-21 2019-10-23 Novartis Ag Composiciones que comprenden anticuerpos dirigidos al factor P y C5
EP2854760B1 (fr) 2012-05-25 2018-10-17 Novartis AG Composition pharmaceutique aqueuse contenant un agent thérapeutique biologique et de la l-arginine, et injection comprenant la composition
US9133269B2 (en) 2012-08-24 2015-09-15 Anaptysbio, Inc. Humanized antibodies directed against complement protein C5
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
BR112015018438A2 (pt) 2013-01-31 2017-07-18 Seoul Nat Univ R&Db Foundation anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
SG10201707518YA (en) * 2013-03-14 2017-10-30 Regeneron Pharma Human antibodies to grem 1
EP3473272A1 (fr) 2013-03-29 2019-04-24 Alexion Pharmaceuticals, Inc. Compositions et procédés pour augmenter la demi-vie sérique d'un agent thérapeutique ciblant c5 complémentaire
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
US10815296B2 (en) 2013-09-16 2020-10-27 Children's Hospital Medical Center Methods of treatment of HSCT-associated thrombotic microangiopathy with eculizumab
CA2926812A1 (fr) 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Methodes pour empecher la mort des cellules photoreceptrices ou reduire le nombre de cellules photoreceptrices mortes
WO2015103438A2 (fr) 2014-01-02 2015-07-09 Genelux Corporation Traitement d'appoint par un virus oncolytique avec des agents qui augmentent l'infectivité du virus
WO2015120130A1 (fr) 2014-02-07 2015-08-13 Novartis Ag Impact de facteurs génétiques sur la progression d'une maladie et réponse aux anticorps anti-c5 dans l'atrophie géographique
AU2015218903B2 (en) 2014-02-20 2020-10-15 Allergan, Inc. Complement component C5 antibodies
JP2017512457A (ja) 2014-02-21 2017-05-25 メディミューン，エルエルシー 抗ｐｃｓｋ９〜ｇｌｐ−１融合物および使用方法
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
JP6718379B2 (ja) 2014-03-20 2020-07-08 インフラルクス ゲーエムベーハー ウイルス性肺炎治療のためのＣ５ａの阻害剤
CN106659146B (zh) 2014-05-05 2020-06-23 再生元制药公司 人源化c5和c3动物
EP3160990A2 (fr) 2014-06-25 2017-05-03 Novartis AG Compositions et procédés pour protéines à action longue
JP6564776B2 (ja) 2014-07-12 2019-08-21 株式会社カネカ 複合太陽電池、太陽電池モジュール、および集光太陽電池
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
SG10201710322VA (en) 2014-12-19 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
CN107428823B (zh) 2015-01-22 2021-10-26 中外制药株式会社 两种以上抗-c5抗体的组合与使用方法
WO2016160756A2 (fr) 2015-03-31 2016-10-06 Alexion Pharmaceuticlas, Inc. Identification et traitement de sous-populations de patients souffrant d'hémoglobinurie paroxystique nocturne
EP3288586A1 (fr) 2015-05-01 2018-03-07 Alexion Pharmaceuticals, Inc. Efficacité d'un anticorps anti-c5 dans la prévention du rejet à médiation par les anticorps chez des receveurs sensibilisés d'une greffe de rein
EP3307318A4 (fr) 2015-06-09 2019-01-16 Children's Hospital Medical Center Algorithme de dosage pour inhibiteur du complément
US20160362482A1 (en) 2015-06-10 2016-12-15 Case Western Reserve University Compositions and methods of modulating b cell response
WO2016201301A1 (fr) 2015-06-12 2016-12-15 Alnylam Pharmaceuticals, Inc. Compositions d'arni de composant du complément c5 et leurs procédés d'utilisation
WO2017035362A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Utilisation de composés inhibiteurs de la voie du complément pour atténuer des réponses immunitaires indésirables associées à une thérapie adoptive par lymphocytes t
WO2017044811A1 (fr) 2015-09-11 2017-03-16 Bruce Andrien Variants d'éculizumab et d'éculizumab glycosylé de recombinaison
EP3356402A1 (fr) 2015-09-28 2018-08-08 Alexion Pharmaceuticals, Inc. Procédés de traitement des déficiences adamts13 et de thrombocytopénie thrombotiques congénitales chez des patients pédiatriques
EP3359566A1 (fr) 2015-10-07 2018-08-15 Alexion Pharmaceuticals, Inc. Procédé pour le traitement de la dégénérescence maculaire liée à l'âge chez un patient
TW201718014A (zh) 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
EP3368073B1 (fr) 2015-10-30 2024-05-15 Alexion Pharmaceuticals, Inc. Procédé d'inhibition d'exacerbations de vasculopathies d'allogreffe médiées par les cellules t
PL3390442T3 (pl) 2015-12-18 2024-03-18 Chugai Seiyaku Kabushiki Kaisha Przeciwciała anty-c5 i sposoby ich stosowania
US20190023775A1 (en) 2016-01-11 2019-01-24 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
WO2017132259A1 (fr) 2016-01-25 2017-08-03 Shire Human Genetic Therapies, Inc. Anticorps anti-c5 à commutation ph améliorée
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
AU2017269839A1 (en) 2016-05-27 2018-11-22 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
CN109310760A (zh) 2016-06-07 2019-02-05 诺华股份有限公司 抗c5抗体给药方案
US20190225678A1 (en) 2016-06-07 2019-07-25 Novartis Ag Anti-c5 antibody for treating patients with complement c5 polymorphism
WO2017214518A1 (fr) 2016-06-10 2017-12-14 Alnylam Pharmaceuticals, Inc. Compositions d'arni du composant c5 du complément et leurs méthodes d'utilisation pour traiter l'hémoglobinurie paroxystique nocturne (hpn)
WO2017218515A1 (fr) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anticorps anti-c5 et leurs utilisations
UA126561C2 (uk) 2016-06-17 2022-11-02 Чугаі Сейяку Кабусікі Кайся Застосування антитіла проти с5
WO2018009588A1 (fr) 2016-07-06 2018-01-11 Macho Daisy Llc Dispositif portable et système pour messagerie audio personnelle
WO2018053039A1 (fr) 2016-09-14 2018-03-22 The Usa, As Represented By The Secretary, Department Of Health & Human Services Méthodes de diagnostic et de traitement de déficience en cd55, d'hyperactivation du complément, de thrombose angiopathique et d'entéropathie à perte de protéine (chaple), une maladie orphelline nouvellement identifiée
JP7256741B2 (ja) 2016-10-12 2023-04-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性
US10802945B2 (en) 2016-12-07 2020-10-13 Ab Initio Technology Llc Differencing of executable dataflow graphs
AU2017376884B2 (en) 2016-12-16 2024-10-03 Samsung Bioepis Co., Ltd Stable aqueous anti-C5 antibody composition
CR20190403A (es) 2017-01-31 2019-10-10 Hoffmann La Roche Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
BR112019018429A2 (pt) 2017-03-06 2020-04-14 Univ Pennsylvania anticorpo, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indíviduo e para reduzir a atividade de um sistema complemento de um indivíduo, e, célula
US11274146B2 (en) 2017-03-23 2022-03-15 The Trustees Of The University Of Pennsylvania Anti-C5a antibodies and uses thereof
WO2018195034A1 (fr) 2017-04-19 2018-10-25 Alexion Pharmaceuticals, Inc. Efficacité d'un anticorps anti-c5 dans la prévention du rejet à médiation par anticorps chez des receveurs sensibilisés d'une greffe de rein
CN111201241A (zh) 2017-06-23 2020-05-26 因弗拉克斯有限责任公司 用C5a活性抑制剂治疗炎性疾病
MX2020006113A (es) 2017-12-13 2020-08-24 Regeneron Pharma Combinaciones de anticuerpos anti-c5 y usos de las mismas.
AU2020334880A1 (en) 2019-08-16 2022-03-24 Regeneron Pharmaceuticals, Inc. High concentration anti-C5 formulations

Also Published As

Publication number Publication date
US20170355757A1 (en) 2017-12-14
IL309975B1 (en) 2025-12-01
MY196006A (en) 2023-03-06
IL263481B2 (en) 2024-06-01
IL324531A (en) 2026-01-01
US10633434B2 (en) 2020-04-28
EP3468990B1 (fr) 2024-03-27
JP2019528039A (ja) 2019-10-10
SG11201810933QA (en) 2019-01-30
IL309975A (en) 2024-03-01
KR20230074831A (ko) 2023-05-31
PH12018502560A1 (en) 2019-10-14
SG10202012243VA (en) 2021-01-28
EP4374922B1 (fr) 2026-02-25
PL3468990T3 (pl) 2024-08-05
SMT202600200T1 (it) 2026-05-12
MX2018015149A (es) 2019-08-21
MA45235A (fr) 2019-04-17
FI3468990T3 (fi) 2024-06-26
MD3468990T2 (ro) 2024-11-30
SI3468990T1 (sl) 2024-07-31
EP3468990A1 (fr) 2019-04-17
DK3468990T3 (da) 2024-06-24
PH12023500007A1 (en) 2024-03-11
IL263481B1 (en) 2024-02-01
EP4374922A3 (fr) 2024-08-28
RS65633B1 (sr) 2024-07-31
PT3468990T (pt) 2024-06-25
NZ749153A (en) 2025-03-28
AU2017283470B2 (en) 2024-03-21
NZ789069A (en) 2025-06-27
JP2023175765A (ja) 2023-12-12
LT3468990T (lt) 2024-06-25
KR20190018166A (ko) 2019-02-21
EP4706763A2 (fr) 2026-03-11
CN109563159A (zh) 2019-04-02
CL2018003563A1 (es) 2019-02-22
JP2025134088A (ja) 2025-09-16
KR102667023B1 (ko) 2024-05-21
WO2017218515A1 (fr) 2017-12-21
MA45235B1 (fr) 2024-07-31
CO2018014413A2 (es) 2019-03-08
KR102534895B1 (ko) 2023-05-24
UA124734C2 (uk) 2021-11-10
AU2017283470A1 (en) 2019-01-03
IL309975B2 (en) 2026-04-01
BR112018075875A2 (pt) 2019-03-19
MX2023001727A (es) 2023-02-22
MX2023001726A (es) 2023-02-22
ES2984352T3 (es) 2024-10-29
CN116769024A (zh) 2023-09-19
CN109563159B (zh) 2023-06-23
JP7102353B2 (ja) 2022-07-19
AU2024204175A1 (en) 2024-07-11
IL263481A (en) 2019-01-31
SMT202400269T1 (it) 2024-07-09
US20230174631A1 (en) 2023-06-08
MY191668A (en) 2022-07-06
HUE067224T2 (hu) 2024-10-28
US11492392B2 (en) 2022-11-08
US11479602B2 (en) 2022-10-25
KR20240070728A (ko) 2024-05-21
JP7368543B2 (ja) 2023-10-24
JP7682964B2 (ja) 2025-05-26
US20200262901A1 (en) 2020-08-20
FI4374922T3 (fi) 2026-05-13
JP2022106952A (ja) 2022-07-20
PH12018502560B1 (en) 2023-11-15
CN116751293A (zh) 2023-09-15
EP4706763A3 (fr) 2026-05-06
EP4374922A2 (fr) 2024-05-29
US20200262900A1 (en) 2020-08-20
CA3027487A1 (fr) 2017-12-21
HRP20240815T1 (hr) 2024-09-27
MY196220A (en) 2023-03-23

Similar Documents

Publication Publication Date Title
MX2023001727A (es) Anticuerpos anti-c5 y usos de los mismos.
MA52773B1 (fr) Anticorps anti-cd3 et leurs utilisations
MA46708B1 (fr) Anticorps anti-pd1 et leurs utilisations
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA38194B1 (fr) Anticorps anti-ceacam5 et leurs utilisations
MA41867B1 (fr) Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
WO2019014328A3 (fr) Anticorps agonistes qui lient cd137 humain et leurs utilisations
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
MA40476A (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
MA43773B1 (fr) Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
MA37946B1 (fr) Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
CR20230528A (es) Anticuerpo anti componente del complemento 1s (c1s)
MA63064B1 (fr) Anticorps anti-tmprss6 et leurs utilisations
MA53186A1 (fr) Anticorps monoclonal qui se lie spécifiquement à cd20
EA201990022A1 (ru) Антитела против c5 и их применение
MA48870B1 (fr) Anticorps anti-sortiline et leurs méthodes d'utilisation
MA50737B1 (fr) Anticorps humains contre la protéine de pic monoclonal du coronavirus du syndrome respiratoire du moyen-orient
MA38502A1 (fr) Anticorps monoclonal humain isole ou son fragment de liaison a l’antigene qui se lie specifiquement a la gremlin-1 humaine utile pour le traitement des fibroses, cancers et l'inhibition de l'angiogenese
EA202092981A1 (ru) Антитела к l1cam и их применение
FR3102175B1 (fr) Nouveaux anticorps monoclonaux therapeutiques humains et leurs utilisations
EA202191060A1 (ru) Анти-npr1 антитела и их применение
MA39559A1 (fr) Anticorps anti récepteur du facteur de nécrose tumorale induit par glucocorticoïdes (gitr) et leurs utilisations